Clinical trials: Irritable Bowel Syndrome With Diarrhea
IBS - Irritable Bowel Syndrome, Diarrhea
Novel Pilot Study to Treat Symptoms of IBS With Diarrhea Using Combination Therapy of a Low-FODMAP Diet and a Neuromodulator
The purpose of this research is to study the added benefit of treating IBS symptoms with a medication called mirtazapine in treating IBS symptoms when paired with a low-FODMAP diet compared to a low-FODMAP diet alone.
- Trial name
- NCT06684470
- Testing
- Mirtazapine
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Mayo Clinic
Irritable Bowel Syndrome With Diarrhea
Efficacy and Safety of DT01 Tablets in Patients With Irritable Bowel Syndrome With Diarrhea
This is a Phase II, double-blind, randomized, 3-arm, placebo-controlled study to evaluate the efficacy and describe the safety of DT01 tablets in adults with IBS-D.
- Trial name
- NCT05719896
- Testing
- DT01 tablets
- Where
- Vietnam
- Volunteers
- 120 people
- Sponsor
- Centre of Clinical Pharmacology, Hanoi Medical University
Irritable Bowel Syndrome With Diarrhea
The Effect of Dietary Supplementation on Intestinal Barrier Function in IBS-D
Many people suffer from Irritable Bowel Syndrome (IBS) every year in the UK. Depending on the stool consistency, IBS can be classified as IBS with diarrhoea (IBS-D), IBS with constipation (IBS-C), or mixed IBS (IBS-M).
- Trial name
- NCT06543498
- Testing
- Lactulose/Mannitol Ratio Test, Serum biomarkers of intestinal permeability, Rome IV questionnaire
- Where
- 2 sites in United Kingdom
- Volunteers
- 32 people
- Sponsor
- Dr Anthony Hobson
Irritable Bowel Syndrome With Diarrhea
Mesalamine Granules for Irritable Bowel Syndrome (IBS) With Diarrhea
The purpose of this study is to determine the daily dose of mesalamine granules that will provide adequate relief from symptoms of IBS with diarrhea.
- Trial name
- NCT01177410
- Testing
- Mesalamine Granules 750 mg, Mesalamine Granules 1500 mg
- Where
- 20 sites in United States
- Volunteers
- 148 people
- Sponsor
- Bausch Health Americas, Inc.
Diarrhea Predominant Irritable Bowel Syndrome
Effect of Ranolazine on Gastrointestinal Motor Function and Pain in Patients With IBS-D
Will Ranolazine improve bowel function and abdominal pain in human subjects with IBS-D?
- Trial name
- Ranolazine (NCT02239926)
- Testing
- Ranolazine
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Mayo Clinic
Irritable Bowel Syndrome - Diarrhoea
Effect of Ebastine in Patients With Diarrhea Predominant Irritable Bowel Syndrome
The goal of this clinical trial is to assess and compare the effect of ebastine and placebo in improving symptoms in patients with diarrhea predominant IBS.
- Trial name
- NCT07114055
- Testing
- ebastine
- Where
- Bangladesh
- Volunteers
- 60 people
- Sponsor
- Md. Hazrat Ali
Chronic Diarrhea, Irritable Bowel Syndrome With Diarrhea
Aldafermin (NGM282) for Chronic Diarrhea Due to Bile Acid Malabsorption (BAM)
This single-center, randomized, double-blind, placebo-controlled study is designed to compare effects of aldafermin, (NGM282), 1 mg, and placebo given daily by subcutaneous injection on bowel functions and hepatic synthesis and…
- Conditions
- Chronic Diarrhea, Irritable Bowel Syndrome With Diarrhea, Bile Acid Malabsorption, Bile Acid Diarrhea
- Trial name
- NCT05130047
- Testing
- Aldafermin
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Michael Camilleri, MD
Diarrhea-predominant Irritable Boewl Syndrome
Efficacy and Safety of Changkang Granules in the Treatment of Irritable Bowel Syndrome With Predominant Diarrhea (Liver qi Affecting the Spleen Pattern)
This study will evaluate the efficacy and safety of Changkang granules in the treatment of irritable bowel syndrome with predominant Diarrhea ( Liver qi affecting the spleen pattern)
- Trial name
- NCT06753890
- Testing
- Changkang granules
- Where
- 30 sites in China
- Volunteers
- 520 people
- Sponsor
- Tasly Pharmaceutical Group Co., Ltd
Irritable Bowel Syndrome
A Study Evaluating Oral Eluxadoline Administered to Pediatric Participants With Irritable Bowel Syndrome With Diarrhea (IBS-D)
This study will assess the long-term safety of oral Eluxadoline administered to pediatric participants with IBS-D who have completed study intervention in the Phase 2 study 3030-202-002 or the Phase 3 study 3030-303-002.
- Trial name
- NCT04880876
- Testing
- 25mg Eluxadoline, 100mg Eluxadoline
- Where
- 6 sites in United States
- Volunteers
- 124 people
- Sponsor
- AbbVie
Irritable Bowel Syndrome - Diarrhoea, Traditional Chinese Medicine (TCM)
Fengliao Changweikang for Diarrhea-predominant Irritable Bowel Syndrome: N-of-1 Trial
Irritable bowel syndrome with diarrhea (IBS-D) is a functional gastrointestinal disorder, with characteristics of defecation related abdominal pain and diarrhea.
- Conditions
- Irritable Bowel Syndrome - Diarrhoea, Traditional Chinese Medicine (TCM), N of 1 Study Design, Efficacy and Safety
- Trial name
- NCT07061184
- Testing
- FLCWK
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Peking Union Medical College Hospital
Irritable Bowel Syndrome With Diarrhea, Irritable Bowel Syndrome
Safety and Efficacy of a Probiotic Supplement in IBS-D
This study aims to assess the safety and efficacy of a single probiotic strain on symptom severity in adults with diarrhea-predominant Irritable Bowel Syndrome (IBS-D).
- Trial name
- IBIS (NCT05754177)
- Testing
- Probiotic
- Where
- Slovenia
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- The Archer-Daniels-Midland Company
Irritable Bowel, Irritable Bowel Syndrome
A Non-Interventional Pilot Study to Explore the Role of Gut Flora in IBS
This study seeks to correlate microbiome sequencing data with information provided by patients and their medical records.
- Conditions
- Irritable Bowel, Irritable Bowel Syndrome, Irritable Bowel Syndrome With Diarrhea, Irritable Bowel Syndrome Mixed
- Trial name
- NCT04214470
- Testing
- No intervention
- Where
- United States
- Sponsor
- ProgenaBiome
Irritable Bowel Syndrome
Phase 3 Study of YM060 in Patients With Diarrhea-predominant Irritable Bowel Syndrome (d-IBS)
This study will examine the efficacy, safety and tolerability of oral dose of YM060, 5-HT3 receptor antagonist, in patients with d-IBS.
- Trial name
- NCT00189696
- Testing
- YM060
- Where
- 4 sites in Japan
- Sponsor
- Astellas Pharma Inc
Irritable Bowel Syndrome With Diarrhea
Study of the Research Medicine CIN-103 in Adults With Irritable Bowel Syndrome With Predominant Diarrhea (IBS-D).
The goal of this clinical trial is to evaluate if the study drug, CIN-103, can help reduce the symptoms associated with irritable bowel syndrome with predominant diarrhea (IBS-D) in adult patients.
- Trial name
- NCT06153420
- Testing
- CIN-103
- Where
- 53 sites in United States
- Volunteers
- 421 people
- Sponsor
- CinPhloro Pharma, LLC
Diarrhea Predominant Irritable Bowel Syndrome
Ability of Mayo Clinic High-performance Liquid Chromatography (HPLC) Method to Measure Fecal Bile Acids
The investigators' hypothesis is that therapy with Colesevelam, reduces fecal bile acid excretion in patients with Irritable Bowel Syndrome (IBS)-diarrhea with prior evidence of increased fecal 48 hour total bile acid excretion.
- Trial name
- NCT02111603
- Testing
- Colesevelam
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Mayo Clinic
Irritable Bowel Syndrome With Diarrhea
To Compare the Efficacy of Drugs in Combination for Treating Irritable Bowel Syndrome Associated With Diarrhea
The goal of this clinical trial is to compare the efficacy of four different drugs in combination for management of irritable bowel syndrome (IBS)-associated diarrhea.
- Trial name
- NCT05867550
- Testing
- Rifaximin 550 MG, Mebeverine 135 MG, Psyllium Husk
- Where
- Pakistan
- Volunteers
- 162 people
- Sponsor
- Bahria University
Pain
Efficacy of Probiotic Bacteria in Subjects With IBS or Functional Diarrhea/ Bloating
To determine if probiotics bacteria, specifically lactobacillus and bifidobacterium, improve gastrointestinal symptoms in patients with IBS, functional diarrhea, or functional bloating.
- Trial name
- NCT00618904
- Testing
- Probiotics - Lactobacillus and bifidobacterium
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- University of North Carolina, Chapel Hill
IBS-C and IBS With Mixed Bowel Habits
Efficacy of Tegaserod in Relieving the Symptoms of Female Patients With Irritable Bowel Syndrome (IBS), Excluding Those With Predominant Diarrhea IBS
Recent literature has demonstrated that the group of IBS sufferers who experience mixed bowel habits may be more similar to IBS-C patients than IBS-D patients.
- Trial name
- NCT00142987
- Testing
- Tegaserod
- Volunteers
- 664 people
- Sponsor
- Novartis
IBS - Irritable Bowel Syndrome, Gut Microbiota
Effects of Continuous Treatment With Rifaximin and Probiotics on the Gut Microbiota of Patients With IBS-D
We will use the latest Rome IV criteria to recruit IBS-D patients and evaluate the effects of repeated treatment with rifaximin and sequential treatment with rifaximin and probiotics on different symptoms and quality of life.
- Trial name
- NCT04074421
- Testing
- Rifaximin, Probiotic Formula
- Where
- China
- Volunteers
- 240 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Irritable Bowel Syndrome
Association Between High Faecal Calprotectin, Increased Intestinal Permeability and Visceral Hypersensitivity in IBS-D Patients
Visceral hypersensitivity, low grade inflammation and increased intestinal permeability are three main pathophysiological mechanisms involved in irritable bowel syndrome. The connexion between these abnormalities is not known.
- Trial name
- SIIMPA (NCT02550704)
- Testing
- Colonoscopy with eleven biopsies in the left colon to assess intestinal permeability
- Where
- France
- Volunteers
- 34 people
- Sponsor
- University Hospital, Rouen